Biomarkers, PARP Inhibitors Vital for Personalized Treatment in Breast Cancer Subtypes

Excerpt:

“Developing predictive biomarkers will be key to treating patients with triple-negative breast cancer (TNBC), especially when choosing a targeted therapy, said Banu K. Arun, MD.

“In a presentation during the 2018 OncLive® State of the Science Summit™ on Breast Cancer, Arun said there is evidence that PARP inhibitors as well as immunotherapy in combination with various agents may be effective in women with TNBC and BRCA1-related breast cancers, but the science isn’t there yet.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


IBM's Watson Extends Cancer Insights to 14 New Centers

“IBM on Tuesday said 14 US cancer treatment centers would join a partnership to get personalized care treatment plans from the company’s Watson supercomputer.

“The project extends the use of Watson for cancer treatment based on a patient’s own DNA and insights from a large database of medical literature and studies.

” ‘Determining the right drug combination for an advanced cancer patient is alarmingly difficult, requiring a complex analysis of different sources of Big Data that integrates rapidly emerging clinical trial information with personalized gene sequencing,’ said Norman Sharpless, of the University of North Carolina’s Lineberger Comprehensive Cancer Center.

” ‘We are partnering with IBM in an effort to solve this decision problem with the help of cognitive technology and to improve the decisions we make with our patients to maximize their chance for cure.’ ”


Myriad's Prolaris(R) Test Significantly Modifies Treatment Decisions for Patients With Prostate Cancer

“Myriad Genetics, Inc. (MYGN) today announced results from PROCEDE 500, a clinical utility study with its Prolaris test, at the 2014 ASCO Genitourinary Cancers Symposium in San Francisco, Calif. The study demonstrated the significant clinical value of Prolaris to physicians who are treating men with prostate cancer. Prolaris is a prognostic test that accurately predicts prostate cancer-specific death and metastases and has been validated in 11 clinical studies with more than 5,000 patients.

” ‘Prolaris has opened the door to a new era of personalized cancer treatment for men with prostate cancer,’ said Michael Brawer, M.D. vice president of medical affairs at Myriad Genetic Laboratories. ‘The Prolaris score is a stronger predictor of prostate cancer death and recurrence than either Gleason score or PSA (prostate specific antigen), and delivers clinically relevant information not provided by any other prognostic test.’ “